63 research outputs found
Theranostic nanoparticles enhance the response of glioblastomas to radiation
YesDespite considerable progress with our understanding of glioblastoma multiforme (GBM) and the precise
delivery of radiotherapy, the prognosis for GBM patients is still unfavorable with tumor recurrence due
to radioresistance being a major concern. We recently developed a cross-linked iron oxide nanoparticle
conjugated to azademethylcolchicine (CLIO-ICT) to target and eradicate a subpopulation of quiescent
cells, glioblastoma initiating cells (GICs), which could be a reason for radioresistance and tumor relapse.
The purpose of our study was to investigate if CLIO-ICT has an additive therapeutic effect to enhance the
response of GBMs to ionizing radiation.
Methods: NSGâ„¢ mice bearing human GBMs and C57BL/6J mice bearing murine GBMs received
CLIO-ICT, radiation, or combination treatment. The mice underwent pre- and post-treatment magnetic
resonance imaging (MRI) scans, bioluminescence imaging (BLI), and histological analysis. Tumor
nanoparticle enhancement, tumor flux, microvessel density, GIC, and apoptosis markers were compared
between different groups using a one-way ANOVA and two-tailed Mann-Whitney test. Additional NSGâ„¢
mice underwent survival analyses with Kaplan–Meier curves and a log rank (Mantel–Cox) test.
Results: At 2 weeks post-treatment, BLI and MRI scans revealed significant reduction in tumor size for
CLIO-ICT plus radiation treated tumors compared to monotherapy or vehicle-treated tumors.
Combining CLIO-ICT with radiation therapy significantly decreased microvessel density, decreased
GICs, increased caspase-3 expression, and prolonged the survival of GBM-bearing mice. CLIO-ICT
delivery to GBM could be monitored with MRI. and was not significantly different before and after
radiation. There was no significant caspase-3 expression in normal brain at therapeutic doses of
CLIO-ICT administered.
Conclusion: Our data shows additive anti-tumor effects of CLIO-ICT nanoparticles in combination with
radiotherapy. The combination therapy proposed here could potentially be a clinically translatable
strategy for treating GBMs
Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial
YesBackground: The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) and aspirin both have proof of
concept for colorectal cancer chemoprevention, aligned with an excellent safety profile. Therefore, we aimed to test
the efficacy of EPA and aspirin, alone and in combination and compared with a placebo, in individuals with sporadic
colorectal neoplasia detected at colonoscopy.
Methods: In a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial, patients aged 55–73 years
who were identified during colonoscopy as being at high risk in the English Bowel Cancer Screening Programme
(BCSP; ≥3 adenomas if at least one was ≥10 mm in diameter or ≥5 adenomas if these were <10 mm in diameter) were
recruited from 53 BCSP endoscopy units in England, UK. Patients were randomly allocated (1:1:1:1) using a secure
web-based server to receive 2 g EPA-free fatty acid (FFA) per day (either as the FFA or triglyceride), 300 mg aspirin per
day, both treatments in combination, or placebo for 12 months using random permuted blocks of randomly varying
size, and stratified by BCSP site. Research staff and participants were masked to group assignment. The primary
endpoint was the adenoma detection rate (ADR; the proportion of participants with any adenoma) at 1 year surveillance
colonoscopy analysed in all participants with observable follow-up data using a so-called at-the-margins approach,
adjusted for BCSP site and repeat endoscopy at baseline. The safety population included all participants who received
at least one dose of study drug. The trial is registered with the International Standard Randomised Controlled Trials
Number registry, number ISRCTN05926847.
Findings: Between Nov 11, 2011, and June 10, 2016, 709 participants were randomly assigned to four treatment groups
(176 to placebo, 179 to EPA, 177 to aspirin, and 177 to EPA plus aspirin). Adenoma outcome data were available for
163 (93%) patients in the placebo group, 153 (85%) in the EPA group, 163 (92%) in the aspirin group, and 161 (91%) in
the EPA plus aspirin group. The ADR was 61% (100 of 163) in the placebo group, 63% (97 of 153) in the EPA group,
61% (100 of 163) in the aspirin group, and 61% (98 of 161) in the EPA plus aspirin group, with no evidence of any
effect for EPA (risk ratio [RR] 0·98, 95% CI 0·87 to 1·12; risk difference –0·9%, –8·8 to 6·9; p=0·81) or aspirin
(RR 0·99 (0·87 to 1·12; risk difference –0·6%, –8·5 to 7·2; p=0·88). EPA and aspirin were well tolerated (78 [44%] of
176 had ≥1 adverse event in the placebo group compared with 82 [46%] in the EPA group, 68 [39%] in the aspirin
group, and 76 [45%] in the EPA plus aspirin group), although the number of gastrointestinal adverse events was
increased in the EPA alone group at 146 events (compared with 85 in the placebo group, 86 in the aspirin group, and
68 in the aspirin plus placebo group). Six upper-gastrointestinal bleeding events were reported across the treatment
groups (two in the EPA group, three in the aspirin group, and one in the placebo group).
Interpretation Neither EPA nor aspirin treatment were associated with a reduction in the proportion of patients with
at least one colorectal adenoma. Further research is needed regarding the effect on colorectal adenoma number
according to adenoma type and location. Optimal use of EPA and aspirin might need a precision medicine approach
to adenoma recurrence.Efficacy and Mechanism Evaluation Programme, a UK Medical Research Council and National Institute for Health Research partnership.Research Development Fund Publication Prize Award winner, November 2018
Ultrasound-triggered therapeutic microbubbles enhance the efficacy of cytotoxic drugs by increasing circulation and tumor drug accumulation and limiting bioavailability and toxicity in normal tissues
Most cancer patients receive chemotherapy at some stage of their treatment which makes improving the efficacy of cytotoxic drugs an ongoing and important goal. Despite large numbers of potent anti-cancer agents being developed, a major obstacle to clinical translation remains the inability to deliver therapeutic doses to a tumor without causing intolerable side effects. To address this problem, there has been intense interest in nanoformulations and targeted delivery to improve cancer outcomes. The aim of this work was to demonstrate how vascular endothelial growth factor receptor 2 (VEGFR2)-targeted, ultrasound-triggered delivery with therapeutic microbubbles (thMBs) could improve the therapeutic range of cytotoxic drugs.
Methods: Using a microfluidic microbubble production platform, we generated thMBs comprising VEGFR2-targeted microbubbles with attached liposomal payloads for localised ultrasound-triggered delivery of irinotecan and SN38 in mouse models of colorectal cancer. Intravenous injection into tumor-bearing mice was used to examine targeting efficiency and tumor pharmacodynamics. High-frequency ultrasound and bioluminescent imaging were used to visualise microbubbles in real-time. Tandem mass spectrometry (LC-MS/MS) was used to quantitate intratumoral drug delivery and tissue biodistribution. Finally, 89Zr PET radiotracing was used to compare biodistribution and tumor accumulation of ultrasound-triggered SN38 thMBs with VEGFR2-targeted SN38 liposomes alone.
Results: ThMBs specifically bound VEGFR2 in vitro and significantly improved tumor responses to low dose irinotecan and SN38 in human colorectal cancer xenografts. An ultrasound trigger was essential to achieve the selective effects of thMBs as without it, thMBs failed to extend intratumoral drug delivery or demonstrate enhanced tumor responses. Sensitive LC-MS/MS quantification of drugs and their metabolites demonstrated that thMBs extended drug exposure in tumors but limited exposure in healthy tissues, not exposed to ultrasound, by persistent encapsulation of drug prior to elimination. 89Zr PET radiotracing showed that the percentage injected dose in tumors achieved with thMBs was twice that of VEGFR2-targeted SN38 liposomes alone.
Conclusions: thMBs provide a generic platform for the targeted, ultrasound-triggered delivery of cytotoxic drugs by enhancing tumor responses to low dose drug delivery via combined effects on circulation, tumor drug accumulation and exposure and altered metabolism in normal tissues
Identification of Stage-Specific Breast Markers using Quantitative Proteomics
YesMatched healthy and diseased tissues from breast cancer patients were analyzed by quantitative proteomics. By comparing proteomic profiles of fibroadenoma (benign tumors, three patients), DCIS (noninvasive cancer, three patients), and invasive ductal carcinoma (four patients), we identified protein alterations that correlated with breast cancer progression. Three 8-plex iTRAQ experiments generated an average of 826 protein identifications, of which 402 were common. After excluding those originating from blood, 59 proteins were significantly changed in tumor compared with normal tissues, with the majority associated with invasive carcinomas. Bioinformatics analysis identified relationships
between proteins in this subset including roles in redox regulation, lipid transport, protein folding, and proteasomal degradation, with a substantial number increased in expression due to Myc oncogene activation. Three target proteins, cofilin-1 and p23 (increased in invasive carcinoma) and membrane copper amine oxidase 3 (decreased in invasive carcinoma), were subjected to further validation. All three were observed in phenotype-specific breast cancer cell lines, normal (nontransformed) breast cell lines, and primary breast epithelial cells by Western blotting, but only cofilin-1 and p23 were detected by multiple reaction monitoring mass spectrometry analysis. All three proteins were detected by both analytical approaches in matched tissue biopsies emulating the response observed with proteomics analysis. Tissue microarray analysis (361 patients) indicated cofilin-1 staining positively correlating with tumor grade and p23 staining with ER positive status; both therefore merit further investigation as potential biomarkers.Cyprus Research Promotion Foundation, Yorkshire Cancer Researc
FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLCγ/COX-2-Mediated Mechanisms
Tumour invasion and metastasis is the most common cause of death from cancer. For epithelial cells to invade surrounding tissues and metastasise, an epithelial-mesenchymal transition (EMT) is required. We have demonstrated that FGFR1 expression is increased in bladder cancer and that activation of FGFR1 induces an EMT in urothelial carcinoma (UC) cell lines. Here, we created an in vitro FGFR1-inducible model of EMT, and used this model to identify regulators of urothelial EMT. FGFR1 activation promoted EMT over a period of 72 hours. Initially a rapid increase in actin stress fibres occurred, followed by an increase in cell size, altered morphology and increased migration and invasion. By using site-directed mutagenesis and small molecule inhibitors we demonstrated that combined activation of the mitogen activated protein kinase (MAPK) and phospholipase C gamma (PLCγ) pathways regulated this EMT. Actin stress fibre formation was regulated by PLCγ activation, and was also important for the increase in cell size, migration and altered morphology. MAPK activation regulated migration and E-cadherin expression, indicating that combined activation of PLCγand MAPK is required for a full EMT. We used expression microarrays to assess changes in gene expression downstream of these signalling cascades. COX-2 was transcriptionally upregulated by FGFR1 and caused increased intracellular prostaglandin E2 levels, which promoted migration. In conclusion, we have demonstrated that FGFR1 activation in UC cells lines promotes EMT via coordinated activation of multiple signalling pathways and by promoting activation of prostaglandin synthesis
Recommended from our members
Intermittent PI3Ko inhibition sustains anti-tumor immunity and curbs irAEs
YesPhosphoinositide 3-kinase δ (PI3Kδ) has a key role in lymphocytes, and inhibitors
that target this PI3K have been approved for treatment of B cell malignancies1–3.
Although studies in mouse models of solid tumours have demonstrated that PI3Kδ
inhibitors (PI3Kδi) can induce anti-tumour immunity4,5, its effect on solid tumours in
humans remains unclear. Here we assessed the effects of the PI3Kδi AMG319 in
human patients with head and neck cancer in a neoadjuvant, double-blind,
placebo-controlled randomized phase II trial (EudraCT no. 2014-004388-20). PI3Kδ
inhibition decreased the number of tumour-infiltrating regulatory T (Treg) cells and
enhanced the cytotoxic potential of tumour-infiltrating T cells. At the tested doses
of AMG319, immune-related adverse events (irAEs) required treatment to be
discontinued in 12 out of 21 of patients treated with AMG319, suggestive of systemic
effects on Treg cells. Accordingly, in mouse models, PI3Kδi decreased the number of
Treg cells systemically and caused colitis. Single-cell RNA-sequencing analysis
revealed a PI3Kδi-driven loss of tissue-resident colonic ST2 Treg cells, accompanied
by expansion of pathogenic T helper 17 (TH17) and type 17 CD8+ T (TC17) cells,
which probably contributed to toxicity; this points towards a specific mode of action
for the emergence of irAEs. A modified treatment regimen with intermittent dosing of
PI3Kδi in mouse models led to a significant decrease in tumour growth without
inducing pathogenic T cells in colonic tissue, indicating that alternative dosing
regimens might limit toxicity
Survival and the growth of pintado (Pseudoplatystoma corruscans) post-larvae on different salinities
Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial
Background
The omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) and aspirin both have proof of concept for colorectal cancer chemoprevention, aligned with an excellent safety profile. Therefore, we aimed to test the efficacy of EPA and aspirin, alone and in combination and compared with a placebo, in individuals with sporadic colorectal neoplasia detected at colonoscopy.
Methods
In a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial, patients aged 55–73 years who were identified during colonoscopy as being at high risk in the English Bowel Cancer Screening Programme (BCSP; ≥3 adenomas if at least one was ≥10 mm in diameter or ≥5 adenomas if these were <10 mm in diameter) were recruited from 53 BCSP endoscopy units in England, UK. Patients were randomly allocated (1:1:1:1) using a secure web-based server to receive 2 g EPA-free fatty acid (FFA) per day (either as the FFA or triglyceride), 300 mg aspirin per day, both treatments in combination, or placebo for 12 months using random permuted blocks of randomly varying size, and stratified by BCSP site. Research staff and participants were masked to group assignment. The primary endpoint was the adenoma detection rate (ADR; the proportion of participants with any adenoma) at 1 year surveillance colonoscopy analysed in all participants with observable follow-up data using a so-called at-the-margins approach, adjusted for BCSP site and repeat endoscopy at baseline. The safety population included all participants who received at least one dose of study drug. The trial is registered with the International Standard Randomised Controlled Trials Number registry, number ISRCTN05926847.
Findings
Between Nov 11, 2011, and June 10, 2016, 709 participants were randomly assigned to four treatment groups (176 to placebo, 179 to EPA, 177 to aspirin, and 177 to EPA plus aspirin). Adenoma outcome data were available for 163 (93%) patients in the placebo group, 153 (85%) in the EPA group, 163 (92%) in the aspirin group, and 161 (91%) in the EPA plus aspirin group. The ADR was 61% (100 of 163) in the placebo group, 63% (97 of 153) in the EPA group, 61% (100 of 163) in the aspirin group, and 61% (98 of 161) in the EPA plus aspirin group, with no evidence of any effect for EPA (risk ratio [RR] 0·98, 95% CI 0·87 to 1·12; risk difference −0·9%, −8·8 to 6·9; p=0·81) or aspirin (RR 0·99 (0·87 to 1·12; risk difference −0·6%, −8·5 to 7·2; p=0·88). EPA and aspirin were well tolerated (78 [44%] of 176 had ≥1 adverse event in the placebo group compared with 82 [46%] in the EPA group, 68 [39%] in the aspirin group, and 76 [45%] in the EPA plus aspirin group), although the number of gastrointestinal adverse events was increased in the EPA alone group at 146 events (compared with 85 in the placebo group, 86 in the aspirin group, and 68 in the aspirin plus placebo group). Six upper-gastrointestinal bleeding events were reported across the treatment groups (two in the EPA group, three in the aspirin group, and one in the placebo group).
Interpretation
Neither EPA nor aspirin treatment were associated with a reduction in the proportion of patients with at least one colorectal adenoma. Further research is needed regarding the effect on colorectal adenoma number according to adenoma type and location. Optimal use of EPA and aspirin might need a precision medicine approach to adenoma recurrence.
Funding
Efficacy and Mechanism Evaluation Programme, a UK Medical Research Council and National Institute for Health Research partnership
Data from: Drug delivery in a tumour cord model: a computational simulation
The tumour vasculature and microenvironment is complex and heterogeneous, contributing to reduced delivery of cancer drugs to the tumour. We have developed an in silico model of drug transport in a tumour cord to explore the effect of different drug regimes over a 72 h period and how changes in pharmacokinetic parameters affect tumour exposure to the cytotoxic drug doxorubicin. We used the model to describe the radial and axial distribution of drug in the tumour cord as a function of changes in the transport rate across the cell membrane, blood vessel and intercellular permeability, flow rate, and the binding and unbinding ratio of drug within the cancer cells. We explored how changes in these parameters may affect cellular exposure to drug. The model demonstrates the extent to which distance from the supplying vessel influences drug levels and the effect of dosing schedule in relation to saturation of drug-binding sites. It also shows the likely impact on drug distribution of the aberrant vasculature seen within tumours. The model can be adapted for other drugs and extended to include other parameters. The analysis confirms that computational models can play a role in understanding novel cancer therapies to optimize drug administration and delivery
- …